Overview

Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The efficacy and safety of the extended treatment to patients with most recent episode manic or mixed who completed previous double blind study (F1D-JE-BMAC [Study BMAC]) will be examined.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Carbamazepine
Lithium Carbonate
Olanzapine
Valproic Acid